NCT03165396.

Trial name or title	Appropriate compatibility of propofol and sevoflurane for orthopaedic surgery of patients with MCI
Methods	RCT, parallel design
Participants	Target number of randomized participants: 100 Inclusion criteria Scheduled for elective orthopaedic surgery, ASA II, 50 to 75 years Exclusion criteria Neurological diseases that may affect cognitive function (e.g. subdural haematoma) Hypothyroidism Alcoholic dementia Type of surgery: orthopaedic surgery Country: China Setting: hospital
Interventions	TIVA group Details: propofol TCI 2.0 to 2.5 μg/mL Inhalational maintenance group Details: 1.3 MAC sevoflurane
Outcomes	Evidence of clinically cognitive function decline (using ApoJ, at 7 days; soluble CD14, at 7 days) Cognitive function (using MMSE, at 24 hours and 7 days postoperatively; and MoCA, at 24 hours and 7 days postoperatively)
Starting date	10 May 2016
Contact information	Haiyun Wang (why@126.com) or Yimeng Chen (chenyimeng5525@163.com)
Notes	Compares two additional groups using propofol at different doses combined with sevoflurane